ZD4190, an RTK inhibitor of vascular endothelial growth factor (VEGF) receptor, appeared to exert an acute effect on αVβ3 integrin expression by downregulating the levels on both tumor cells and the endothelium as early as 2 h after the first drug administration, and this finding corresponded with reduced tumor 18F-FPPRGD2 uptake. Here, VEGFA is linked to neoplasm.